We also have to take into account the evidence that SGLT2 inhibitors, when administered to different experimental models of non-diabetic nephropathy, may give rise to different, sometimes conflicting, results, as summarized in Table 1, Table 2, Table 3 and Table 4. This evidence concerns the gene SLC5A2 and diabetic kidney disease.